lonquex
teva b.v. - lipegfilgrastim - neutropenia - immunostimulants, , colony stimulating factors - lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
lonquex 6mg0.6ml solution for injection pre-filled syringes
teva uk ltd - lipegfilgrastim - solution for injection - 10mg/1ml
lonquex
abic marketing ltd, israel - lipegfilgrastim - solution for injection - lipegfilgrastim 6 mg / 0.6 ml - lipegfilgrastim - reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
lonquex solution for injection in pre-filled syringe 6mg0.6ml
teva pharmaceutical investments singapore pte. ltd. - lipegfilgrastim - injection, solution - lipegfilgrastim 6.00 mg/0.6ml
lonquex
teva pharma (new zealand) limited - lipegfilgrastim 10 mg/ml; ; - solution for injection - 6 mg/0.6ml - active: lipegfilgrastim 10 mg/ml excipient: acetic acid polysorbate 20 sodium hydroxide sorbitol water for injection - reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).